Is the iShares Global Healthcare ETF the best long-term investment in 2020?

Is the iShares Global Healthcare ETF (ASX: IXJ) the best long-term ASX shares investment in 2020?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When thinking of ASX shares that might prove a good investment in 2020, one's mind immediately jumps to the healthcare sector.

Healthcare is an evergreen, recession-proof industry at the best of times, but I think 2020 has highlighted the importance that healthcare companies can play in the global economy.

The ASX has many top healthcare companies in its own right. You have the beloved CSL Limited (ASX: CSL) – now the ASX's largest company. There's also Ramsay Health Care Limited (ASX: RHC) and Cochlear Limited (ASX: COH).

These companies do have global exposure. But I think investors looking for even more diversification should look at the iShares Global Healthcare ETF (ASX: IXJ).

A healthy ETF for your portfolio?

The iShares Global Healthcare ETF (exchange-traded fund) tracks a basket of over 100 healthcare shares from around the world. You are getting the truly massive global healthcare companies like Johnson & Johnson (maker of Band-Aids and Listerine), Pfizer (Lyrica, Robitussin and the little blue pill) and Novartis (Ritalin). For some perspective here, Johnson & Johnson alone is over 4 times as large as CSL by market capitalisation.

This ETF is heavily weighted toward US shares with a 68% weighting, but you also get a fair chunk of exposure to Switzerland, Japan and the United Kingdom.

The durability and 'recession-proof' nature of this industry can be seen in these performance numbers. IXJ has returned 17.23% in the last year alone, and an average of 9.13% per annum over the last 5 years. That compares very well against the S&P/ASX 200 Index (ASX: XJO), which has returned -14.42% and 1.39% over the same periods respectively (including dividend reinvestment).

A management fee of 0.47% per annum isn't the cheapest on the ETF market, but it's still not too expensive in my view (remember, 0.47% translates to $4.70 for every $1,000 invested every year). For this unique exposure to the global healthcare sector, I think it's well worth it for this investment.

Thus, I think the IXJ ETF could be used as a strong 'core' holding in any ASX portfolio, whether it be growth or income-focused. You shouldn't expect massive returns every year (like the last year has seen for this ETF), but I think it's a strong and stable investment that you don't have to worry about becoming obsolete with technological change or shifting consumer tastes like some other ASX shares.

Sebastian Bowen owns shares of Johnson & Johnson, Pfizer and Ramsay Health Care Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has recommended Cochlear Ltd. and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »